Open access
Longitudinal Economic Burden for Non–Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database
A. Fraslin
S. Benhamou
Thierry Lebret
Y. Neuzillet
S. Droupy
Grégoire Poinas
D. Vordos
Laurent Guy
G. Marcq
Marc Schneider
P. Coloby
A. Monges
A. Méjean
E. Potiron
J. Descotes
Pascal Eschwege
G. Loison
C. Krucker
A. Mangin
François Radvanyi
Y. Allory
Maryam Karimi
J. Bonastre
Medicine
Abstract
Take Home Message Costs of non-muscle invasive bladder cancer are highly heterogeneous and strongly influenced by disease severity and early treatment. Real-world, stage-specific estimates are essential for informing cost-effectiveness analyses and guiding health care decision-making.